Objectives: In RA patients in longstanding clinical and radiographic remission, achieved by a DAS28-driven T2T strategy, to investigate if US signs of inflammation differs between RA patients, treated with csDMARD or bDMARD (+/-csDMARD). Methods: Eighty-seven patients with RA in longstanding clinical (continuous DAS28<2.6 for the preceding year) and radiographic (no progression for at least 1 year) remission, were included in the study. US of elbows, wrists, MCP2-5, knees, ankles and MTP2-5 were performed using a GE LOGIQE9 US unit. Each joint was scored for grey-scale synovitis (GSS) and synovial color Doppler activity (CDA) by a 0-3 semi-quantitative score. Ultrasound remission was defined in two ways: either no (GSS=0 and CDA=0) or minimal (GSS≤1 and CDA=0) inflammation in any of the 24 assessed joints. Results: Clinical characteristics and US findings are shown in the table. All 87 patients fulfilled DAS28 remission criteria at entry and CDAI remission was fulfilled in 76% and 79% in the csDMARD and bDMARD group, respectively. Complete absence of any signs of US inflammation (GSS=0 and CDA=0) was seen in 0% and 14% in the csDMARD and bDMARD groups, respectively (p=0.01), while minimal US inflammation (GSS≤1 and CDA=0) was seen in 33% and 40% (NS). CDA in at least one joint was seen in the majority of patients in both groups, 58% and 57% respectively.
csDMARD (n=45) bDMARD ( Values are given as numbers (percentages) and median (range). Fisher's exact or Mann-Whitney test used for comparisons.
Conclusions:
The majority of RA patients, in this cohort of patients in longstanding clinical and radiographic remission obtained through a DAS28 driven T2T strategy, had signs of inflammation as assessed by US, irrespective of receiving biologic treatment or not. For patients in clinical remission, the consequences of sustained US inflammation still have to be investigated. Background: Up to 40% of patients with cutaneous psoriasis may develop psoriatic arthritis (PsA). Early detection of PsA by advanced imaging techniques results in better response to therapy. There are very few studies evaluating the MRI appearance in feet of patients with psoriasis and PsA. Objectives: This study sought to evaluate inflammation at the small joints of feet in a subset of psoriasis patients without clinical arthritis, using an office-based extremity MRI (eMRI) as compared to the findings in overt PsA patients. Methods: Patients with psoriasis were recruited from Dermatology and Rheumatology clinics of a tertiary care institution in southern India were divided into those without arthritis (PsO) and PsA groups. All consenting patients underwent non-contrast eMRI of the right foot. Demographic and physical examination details were recorded. PsO patients completed the early arthritis in psoriasis (EARP) questionnaire. Two trained readers scored the MRI inflammation (synovitis, tenosynovitis, osteitis) using a modification of the PsAMRI scores (PsAMRIS). 1 Inter-reader agreement was assessed in a random subset of 42 cases using intra-class correlation coefficient (ICC). Proportion of patients with any sign of MRI inflammation was noted. Mann-Whitney U test was used to compare inflammation scores of PsO with PsA patients. Clinical variables were compared with inflammation scores for any association. Results: A total of 83 patients (30 PsA and 53 PsO) with 75% males and mean age of 42.2±11.6 years were included. ICC for all three variables between the readers was very good (>0.8). There was no statistical difference between the median eMRI inflammatory scores in PsA and PsO patients (p=0.493). Evidence of inflammation was present in 64% and 67% patients in the PsO and PsA groups, respectively (Table 1 ). Higher NAPSI scores were associated with presence of MRI inflammation (p=0.022). Background: When diagnosing inflammatory arthritis (IA) early, focal joint imaging may not reflect the overall inflammatory burden/distribution. Whole body MRI (WBMRI) offers the potential to feasibly scan most joints in a single session. Objectives: The aims were (i) to describe the WBMRI pattern of disease in early IA (ii) to identify patterns associated with subsequent definite IA. Methods: Patients were recruited with early inflammatory joint symptoms and/or signs of IA. Clinical data included age, gender, symptom duration, CRP, HLA-B27, RF, CCP Ab and tender/swollen joint counts. Using 3T WBMRI, T2-weighted fat suppressed spine/SIJ images pre contrast and 3D VIBE Dixon images of peripheral joints and entheses post IV contrast were acquired. Images were consensus scored for inflammation/erosion at the spine, SIJ, GHJ, SCJ, wrist, MCP, PIP, hip, knee, ankle, mid/hind foot, MTP and IP joints plus shoulder, ASIS, greater trochanter, knee, Achilles and plantar fascia entheses. Subjects were clinically classified at baseline and 1 year as undifferentiated arthritis (UA), CCP+RA, CCP-RA or Spondyloarthropathy (SpA). Clinicians were unaware of the MRI findings. Results: 39 patients (23 female) were recruited; mean age 43 years, median symptom duration 18 months (7, 24), TJC 5 (2,11), SJC 1 (0,3) and CRP 2 (2,2). At baseline, 14 were classified as definite disease (RA or SpA) and 25 (14 female) as UA with mean age 40 years, median symptom duration 16.5 months (9.8, 24.3), TJC 3 (1,8), SJC 0 (0,1), CRP 2 (2,2) and 3 (12%) were HLA-B27 positive. The distribution of WBMRI findings in the classified (i.e. definite IA) group was predominantly small joint and tendon-based in the CCP+ RA group, large joint based with 50% having SIJ disease in the CCP-group and similar findings in the SpA group. In the non-classified group (i.e. pUA and rUA), the distribution in pUA was both axial and peripheral, involving joints and entheses, with 25% having SIJ disease. In comparison, findings in the rUA group were similarly distributed but less frequent with no cases of SIJ disease. After 1 year of clinical/laboratory follow-up, 8 were identified as pUA, 6 rUA, 7 CCP+RA, 6 CCP-RA and 12 as SpA. Table 1 shows WBMRI disease distribution by 1 year diagnostic category. The inclusion of affected WBMRI sites in the diagnostic work-up would have appropriately classified 6 further cases of definite SpA, 3 from the pUA and 3 from the CCP-RA groups. Background: There is a short window of opportunity for early diagnosis and treatment of rheumatoid arthritis, that may be crucial for reaching remission and a low rate of radiographic progression. High resolution power doppler ultrasonography (PDUS) is helpful in early detection of synovitis and allows an accurate classification of patients with joint inflammation. Objectives: To establish wether the presence of basal power doppler signal in patients with very early arthritis may be helpful in order to establish the risk of final diagnosis of rheumatoid arthritis according ACR criteria 1987 at a year of follow up. Methods: We studied the presence of ultrasonographic Power Doppler (PD) signal on 28 joints (shoulders, elbows, wrists, MCPs, PIPs, knees) and 44 joints (28 joints and in addition hips, ankles, tarsus, and MTPs), with a mid-range equipment GE L5, in 70 patients with suspected early arthritis The patients were included with at least one of the following inclusion criteria: a) Swelling in 2 or more joints b) pain in MCPs, MTPs and/or the wrists c) morning stiffness of more than 30 minutes with <12 months of duration of the symptoms. Presence or not basal erosions (score ≥2 in at least one joint by modified Sharp method) for each patient were registered (65 patients with basal hands and feet radiology available). Presence of RF and ACPA positive were recorded as well. At one year follow-up was established whether patients met criteria for RA according1987 ACR or not. Statistical study: Chi-square, Fisher exact test, p univariant and Odds Ratio calculation. Results: The presence of basal power doppler signal in ≥1 joints of 44 (PD44) in baseline visit shows statistically significant association to RA diagnosis at 12 months by ACR 1987 classification criteria, p=0.003, OR=5, 43 (1, 24) but the presence of at least one joint with power doppler signal of 28 joints (PD28) did not (p=0.051). Presence hypertrophic synovium with PD44 or not, in at least one joint (HSORPD44) was associated to RA diagnosis as well p=0.024; OR 10,24 (1, 28) . RF was positive in 18/70 (25,71%) and was associated to RA diagnosis (p 0.003, OR 8, 31 (1, 64) , as well as FR/ACPA, positive in 20/70 (28,57%), p=0.001 OR 10 (2,10-47,58). PD44 in addition to positive RF was associated to RA p=0. 003, OR 12, 93 (1, 94) . Presence of basal radiographic erosions (BRE) was associated to RA, p=0.001 OR 7, 72 (2, 8) . PD44 in addition to BRE was significantly associated to RA p=0. 0005, OR 29, 33 (3, 37) . PD28 in addition to RF or BRE was significantly associated to RA respectively p 0. 0005 OR 24, 20 (2, 93 (1, 94) .
The presence of at least one joint with power doppler signal of 44 joints (PD44) on baseline visit may help to predict the RA diagnosis at 12 months of follow up according to criteria ACR 1987, in patients with early RA. PD 44 in addition to classic RA factors (RF and basal radiographic erosions) increased the risk final of RA, till more than three times in case of concomitant basal PD44 and radiographic erosions. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6282
